These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17583928)

  • 1. Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer.
    Borbas KE; Ferreira CS; Perkins A; Bruce JI; Missailidis S
    Bioconjug Chem; 2007; 18(4):1205-12. PubMed ID: 17583928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.
    Okarvi SM; AlJammaz I
    Molecules; 2019 Aug; 24(17):. PubMed ID: 31470531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel polar single amino acid chelates for technetium-99m tricarbonyl-based radiopharmaceuticals with enhanced renal clearance: application to octreotide.
    Maresca KP; Marquis JC; Hillier SM; Lu G; Femia FJ; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    Bioconjug Chem; 2010 Jun; 21(6):1032-42. PubMed ID: 20402463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, radiolabeling and in vitro and in vivo characterization of tumor-antigen- and antibody-derived peptides for the detection of breast cancer.
    Okarvi SM; Jammaz IA
    Anticancer Res; 2009 Apr; 29(4):1399-409. PubMed ID: 19414394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers.
    Ferreira CS; Matthews CS; Missailidis S
    Tumour Biol; 2006; 27(6):289-301. PubMed ID: 17033199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-MUC1 aptamers: radiolabelling with (99m)Tc and biodistribution in MCF-7 tumour-bearing mice.
    Pieve CD; Perkins AC; Missailidis S
    Nucl Med Biol; 2009 Aug; 36(6):703-10. PubMed ID: 19647177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes.
    Boswell CA; Sun X; Niu W; Weisman GR; Wong EH; Rheingold AL; Anderson CJ
    J Med Chem; 2004 Mar; 47(6):1465-74. PubMed ID: 14998334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors.
    Xiang D; Zheng C; Zhou SF; Qiao S; Tran PH; Pu C; Li Y; Kong L; Kouzani AZ; Lin J; Liu K; Li L; Shigdar S; Duan W
    Theranostics; 2015; 5(10):1083-97. PubMed ID: 26199647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC1-Targeted Radiopharmaceuticals in Cancer Imaging and Therapy.
    Maleki F; Rezazadeh F; Varmira K
    Mol Pharm; 2021 May; 18(5):1842-1861. PubMed ID: 33821638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update: aptamers as novel radiopharmaceuticals: their applications and future prospects in diagnosis and therapy.
    Missailidis S; Perkins A
    Cancer Biother Radiopharm; 2007 Aug; 22(4):453-68. PubMed ID: 17803440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of newly designed phosphonate based bone-seeking agent.
    Srivastava P; Tiwari AK; Chadha N; Chuttani K; Mishra AK
    Eur J Med Chem; 2013 Jul; 65():12-20. PubMed ID: 23688696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical aspects of radiolabeled aptamers in diagnostic nuclear medicine: A new class of targeted radiopharmaceuticals.
    Farzin L; Shamsipur M; Moassesi ME; Sheibani S
    Bioorg Med Chem; 2019 Jun; 27(12):2282-2291. PubMed ID: 30502114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-MUC1 nano-aptamers for triple-negative breast cancer imaging by single-photon emission computed tomography in inducted animals: initial considerations.
    Santos do Carmo F; Ricci-Junior E; Cerqueira-Coutinho C; Albernaz MS; Bernardes ES; Missailidis S; Santos-Oliveira R
    Int J Nanomedicine; 2017; 12():53-60. PubMed ID: 28053523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agents.
    Harris TD; Cheesman E; Harris AR; Sachleben R; Edwards DS; Liu S; Bartis J; Ellars C; Onthank D; Yalamanchili P; Heminway S; Silva P; Robinson S; Lazewatsky J; Rajopadhye M; Barrett J
    Bioconjug Chem; 2007; 18(4):1266-79. PubMed ID: 17579472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-MUC1 aptamer: A potential opportunity for cancer treatment.
    Nabavinia MS; Gholoobi A; Charbgoo F; Nabavinia M; Ramezani M; Abnous K
    Med Res Rev; 2017 Nov; 37(6):1518-1539. PubMed ID: 28759115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor targeting using anti-epidermal growth factor receptor (ior egf/r3) immunoconjugate with a tetraaza macrocyclic agent (DO3A-EA).
    Mishra G; Panwar P; Mishra AK
    Mol Imaging; 2012; 11(5):408-16. PubMed ID: 22954185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of biodistribution profile of monoclonal antibodies nanoparticles and aptamers in rats with breast cancer.
    Cerqueira-Coutinho C; Missailidis S; Alessandra-Perini J; Machado DE; Perini JA; Santos-Oliveira R
    Artif Cells Nanomed Biotechnol; 2017 May; 45(3):598-601. PubMed ID: 28211299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties.
    Knogler K; Grünberg J; Novak-Hofer I; Zimmermann K; Schubiger PA
    Nucl Med Biol; 2006 Oct; 33(7):883-9. PubMed ID: 17045168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of chelate conjugation on a newly identified tumor-targeting peptide.
    Mier W; Zitzmann S; Krämer S; Reed J; Knapp EM; Altmann A; Eisenhut M; Haberkorn U
    J Nucl Med; 2007 Sep; 48(9):1545-52. PubMed ID: 17704241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept.
    He J; Liu G; Gupta S; Zhang Y; Rusckowski M; Hnatowich DJ
    J Nucl Med; 2004 Jun; 45(6):1087-95. PubMed ID: 15181145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.